Competitive androgen receptor antagonists are used to treat prostate cancer but, even in the presence of such drugs, overexpression of androgen receptors can drive cellular proliferation ...

Although it has yet to be shown whether these results can be extrapolated to other β 1 AR antagonists with differing pharmacological properties to bucindolol, this study has shown that a drug ...

Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of ...

In an attempt to block this refractory state, competitive androgen receptor antagonists (antiandrogens) are often combined with drugs that block androgen production (mainly analogs of luteinizing ...